Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1016/j.intimp.2021.107622 http://scihub22266oqcxt.onion/10.1016/j.intimp.2021.107622 33895475!8006194!33895475     free     free     free Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 209.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Int+Immunopharmacol 2021 ; 97 (ä): 107622 Nephropedia Template TP {{tp|p=33895475|t=2021. Potential SARS-CoV-2 vaccines: Concept, progress, and challenges |pdf=|usr=}}{{33895475}} gab.com Text Potential SARS-CoV-2 vaccines: Concept, progress, and challenges JO: Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33895475 #FOAvip Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in many countries have announced their vaccine research programs and progress against the COVID-19. While most vaccines go through the designation and preparation stages, some of them are under evaluation for efficacy among animal models and clinical trials, and three approved vaccine candidates have been introduced for limited exploitation in Russia and China. An effective vaccine must induce a protective response of both cell-mediated and humoral immunity and should meet the safety and efficacy criteria. Although the emergence of new technologies has accelerated the development of vaccines, there are several challenges on the way, such as limited knowledge about the pathophysiology of the virus, inducing humoral or cellular immunity, immune enhancement with animal coronavirus vaccines, and lack of an appropriate animal model. In this review, we firstly discuss the immune responses against SARS-CoV-2 disease, subsequently, give an overview of several vaccine platforms for SARS-CoV-2 under clinical trials and challenges in vaccine development against this virus. Twit Text FOAVip Potential SARS-CoV-2 vaccines: Concept, progress, and challenges ????Int Immunopharmacol http://www.kidney.de/pget.php?&tw=1&pmid=33895475 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=33895475 #FOAvip English Wikipedia <ref>{{Cite pmid|33895475}}</ref> Potential SARS-CoV-2 vaccines: Concept, progress, and challenges #MMPMID33895475 Hosseini SA; Zahedipour F; Mirzaei H; Kazemi Oskuee R Int Immunopharmacol 2021[Aug]; 97 (ä): 107622 PMID33895475show ga Since September 2020, the world has had more than 28 million cases of coronavirus disease 2019 (COVID-19). Many countries are facing a second wave of the COVID-19 outbreak. A pressing need is evident for the development of a potent vaccine to control the SARS-CoV-2. Institutions and companies in many countries have announced their vaccine research programs and progress against the COVID-19. While most vaccines go through the designation and preparation stages, some of them are under evaluation for efficacy among animal models and clinical trials, and three approved vaccine candidates have been introduced for limited exploitation in Russia and China. An effective vaccine must induce a protective response of both cell-mediated and humoral immunity and should meet the safety and efficacy criteria. Although the emergence of new technologies has accelerated the development of vaccines, there are several challenges on the way, such as limited knowledge about the pathophysiology of the virus, inducing humoral or cellular immunity, immune enhancement with animal coronavirus vaccines, and lack of an appropriate animal model. In this review, we firstly discuss the immune responses against SARS-CoV-2 disease, subsequently, give an overview of several vaccine platforms for SARS-CoV-2 under clinical trials and challenges in vaccine development against this virus. |*COVID-19/immunology/prevention & control/therapy[MESH] |Animals[MESH] |COVID-19 Serotherapy[MESH] |COVID-19 Vaccines/adverse effects/*therapeutic use[MESH] |Clinical Trials as Topic[MESH] |Humans[MESH] |Immunization, Passive[MESH] |Reinfection/immunology[MESH]Potential SARS-CoV-2 vaccines: Concept, progress, and challenges (epmc).pdf DeepDyve Pubget Overpricing